Resumen de: US2025359753A1
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
Resumen de: US2025361504A1
The present disclosure relates, in general, to methods of preparing a spatial proteome and/or transcriptome sequencing library. The spatial proteome and/or transcriptome sequencing library from a biological sample is useful, in some aspects, to determine a genetic profile and help diagnose a subject who has or is at risk of having a disorder, and improve treatment of the subject.
Resumen de: US2025191903A1
Provided are methods for determining the apolipoprotein E (ApoE) phenotype in a sample by mass spectrometry; wherein the ApoE allele(s) present in the sample is determined from the identity of the ions detected by mass spectrometry. In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.
Resumen de: CN120457337A
The present disclosure provides a method of preparing a biosensor for detecting Alzheimer's disease biomarkers, comprising depositing an alumina film on a Si substrate by an atomic layer deposition system to form an Al2O3/Si substrate; depositing an electric contact part Cr/Au on the Al2O3/Si substrate through a thermal evaporator, and forming a source electrode, a drain electrode and a planar grid electrode on the Al2O3/Si substrate; providing double-layer graphene on the Al2O3/Si substrate through thermal annealing in a vacuum environment; performing low-damage plasma treatment (LDPT) on the double-layer graphene with a mixture of oxygen and hydrogen to form a graphene oxide/graphene (GO/G) layered composite material on the Al2O3/Si substrate; an antibody is immobilized on the surface of a GO/G layered composite material by a reaction between an amine group of the antibody and a carboxyl group of GO of the GO/G layered composite material, where the antibody is specific for p-tau217 protein.
Resumen de: US2025355001A1
The invention relates to an in vitro method for detecting a tau protein fragment in a sample from a patient wherein the amino acid sequence of the fragment consists of amino acid residues within residues 113 to 379 of SEO ID NO: 1. The method may use a specific binding molecule, such as an antibody, directed to key epitopes of tau. The invention may find applications in diagnostics of tauopathics.
Resumen de: US2025355002A1
The invention provides antibodies and binding fragments thereof that specifically binds to TDP-43 cryptic exon-encoded neoepitopes, and methods of use thereof. The methods of use include methods of detecting TDP-43 loss of function, methods of detection and/or diagnosing TDP-43 associated diseases, and methods of monitoring disease progression and/or response to therapy. The invention also provides a kit including the antibodies and binding fragments thereof.
Resumen de: WO2025240658A1
Neprilysin inhibitors are used for the treatment of patients with Alzheimer's disease or other proteinopenic diseases of the CNS. The patients selected for therapy may be selected based on confirmed biomarker diagnosis of disease, along with a reduced Aβ level.
Resumen de: US2024310389A1
This document provides methods and materials related to screening for and treating Alzheimer's disease (AD), including late-onset Alzheimer's disease (LOAD).
Nº publicación: CN120981196A 18/11/2025
Solicitante:
戴尔戴莫股份公司
Resumen de: WO2024148357A2
U-p53 peptide P1 is useful in the determination of the rate of progression of Alzheimer's disease (AD). By quantitating the level of U-p53 peptides in a subject's biological sample, the rate of progression of Alzheimer's disease at the pre-clinical and prodromal stages of the disease in a subject can be determined.